GPBAR1 and metabolic dysfunction-associated steatohepatitis: In the present study we report that a dual FXR and GPBAR1 ligand, BAR502, exerts beneficial effects in a rodent model of NASH and fully reverses the development of NASH like features in mice feed an HFD–F, a well validated model of NASH and insulin resistance.